Influence/NN
of/IN
estradiol/NN
and/CC
tamoxifen/NN
on/IN
susceptibility/NN
of/IN
human/JJ
breast/NN
cancer/NN
cell/NN
lines/NNS
to/TO
lysis/NN
by/IN
lymphokine-activated/JJ
killer/NN
cells/NNS
./.

The/DT
design/NN
of/IN
combination/NN
hormonal/JJ
and/CC
immunotherapeutic/JJ
protocols/NNS
for/IN
breast/NN
cancer/NN
patients/NNS
may/MD
be/VB
facilitated/VBN
by/IN
analysis/NN
of/IN
preclinical/JJ
in/FW
vitro/FW
model/JJ
systems/NNS
./.
=====
Estrogen/NN
receptor/NN
positive/JJ
(/(
ER+/JJ
:/:
MCF-7/NN
)/)
and/CC
negative/JJ
(/(
ER-/JJ
:/:
MDA-MB-231/NN
)/)
human/JJ
breast/NN
cancer/NN
cell/NN
lines/NNS
were/VBD
utilized/VBN
to/TO
evaluate/VB
the/DT
effects/NNS
of/IN
tamoxifen/NN
(/(
TAM/NN
)/)
and/CC
estradiol/NN
(/(
E2/NN
)/)
on/IN
modulation/NN
of/IN
breast/NN
cancer/NN
target/NN
susceptibility/NN
to/TO
lysis/NN
by/IN
lymphokine-activated/JJ
killer/NN
(/(
LAK/NN
)/)
cells/NNS
./.
=====
E2-stimulated/JJ
ER+/JJ
cells/NNS
were/VBD
more/RBR
susceptible/JJ
to/TO
lysis/NN
by/IN
LAK/NN
cells/NNS
than/IN
corresponding/VBG
TAM-treated/JJ
or/CC
control/NN
cells/NNS
,/,
while/IN
treatment/NN
of/IN
ER- cells/NNS
with/IN
either/CC
E2/NN
or/CC
TAM/NN
alone/RB
did/VBD
not/RB
alter/VB
from/IN
control/NN
their/PRP$
susceptibility/NN
to/TO
this/DT
immune-mediated/JJ
lysis/NN
./.
=====
All/DT
ER+/JJ
and/CC
ER-cells/NNS
tested/VBN
remained/VBD
sensitive/JJ
after/IN
treatment/NN
with/IN
TAM/NN
to/TO
lysis/NN
by/IN
LAK/NN
cells/NNS
./.
=====
In/IN
addition/NN
,/,
an/DT
adenocarcinoma/NN
reactive/JJ
human-mouse/JJ
chimeric/JJ
monoclonal/JJ
antibody/NN
(/(
ING-1/NN
)/)
was/VBD
able/JJ
to/TO
significantly/RB
boost/VB
in/FW
vivo/FW
generated/VBN
LAK/NN
cell-mediated/JJ
lysis/NN
of/IN
control/NN
,/,
E2-treated/JJ
,/,
and/CC
TAM-treated/JJ
ER+/JJ
and/CC
ER-cells/NNS
./.
=====
These/DT
in/FW
vitro/FW
results/NNS
provide/VBP
a/DT
preclinical/JJ
rationale/NN
for/IN
in/FW
vivo/FW
testing/NN
of/IN
TAM/NN
,/,
interleukin-2/NN
(/(
IL-2/NN
)/)
,/,
and/CC
breast/NN
cancer/NN
reactive/JJ
antibody-dependent/JJ
cellular/JJ
cytotoxicity/NN
facilitating/VBG
antibody/NN
in/IN
patients/NNS
with/IN
refractory/JJ
or/CC
high/JJ
risk/NN
breast/NN
cancer/NN
./.